Akèy › Kansè Poumon ki pa ti selil › New Mexico › Albuquerque
Etid klinik pou Kansè Poumon ki pa ti selil nan Albuquerque, NM
18 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Albuquerque (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- University of New Mexico Cancer Center, Albuquerque
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Ap rekriteFaz 2/3
- University of New Mexico - Comprehensive Cancer Center, Albuquerque
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- University of New Mexico Cancer Center, Albuquerque
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Ap rekriteFaz 3
- University of New Mexico Cancer Center, Albuquerque
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- University of New Mexico Comprehensive Cancer Center, Albuquerque
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- University of New Mexico, Albuquerque
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Ap rekriteFaz 2
- New Mexico Oncology Hematology Consultants, Ltd, Albuquerque
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
Ap rekriteEtid obsèvasyon
- New Mexico Oncology Hematology Consultants, Albuquerque
An External Control Arm Study in Non-Small Cell Lung Cancer
Ap rekriteEtid obsèvasyon
- New Mexico Oncology Hematology Consultants, Albuquerque
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- University of New Mexico Comprehensive Cancer Center, Albuquerque
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Ap rekriteFaz 3
- Research Site, Albuquerque
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Ap rekriteFaz 3
- University of New Mexico Comprehensive Cancer Center ( Site 0135), Albuquerque
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- University of New Mexico Cancer Center, Albuquerque
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- University of New Mexico Cancer Center, Albuquerque
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Lovelace Medical Center-Saint Joseph Square, Albuquerque
- University of New Mexico Cancer Center, Albuquerque
- Lovelace Women's Hospital, Albuquerque
- ak 1 plis
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Ap rekriteFaz 1/2
- Presbyterian Kaseman Hospital (site 208), Albuquerque
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Albuquerque
BostonGene and Exigent Genomic INsight Study
Ap rekriteEtid obsèvasyon
- New Mexico Cancer Center, Albuquerque
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Albuquerque
- Kansè nan tete17 etid
- Kansè ovè15 etid
- Kansè (tout kalite)14 etid
- Kansè poumon14 etid
- Kansè Metastatik12 etid
- Kansè Endomèt12 etid
- Dyabèt Tip 211 etid
- Maladi kadyovaskilè10 etid
- Melanom9 etid
- Leksemi mieloïd egi9 etid
- Kansè pwostat9 etid
- Maladi ren kwonik8 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.